Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-GD2 4th Generation Chimeric Antigen Receptor-modified T Cells (4SCAR-GD2) Targeting Refractory and/or Recurrent Neuroblastoma

NCT02765243 is registered in ClinicalTrials.gov with Zhujiang Hospital as lead sponsor.

NCT NCT02765243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02765243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-GD2 4th Generation Chimeric Antigen Receptor-modified T Cells (4SCAR-GD2) Targeting Refractory and/or Recurrent Neuroblastoma
Lead sponsor
Zhujiang Hospital
Phase
Phase 1
Overall status
Completed
Start date
January 1, 2016
Completion date
December 30, 2023
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

effects of immunotherapy, neuroblastoma